

## DATASHEET

Version 20181206

# IFN- $\lambda$ 1, Human

**Cat. No.:** Z02742-20

**Size:** 20.0 ug

**Synonyms:** Interferon- $\lambda$ 1 ( IFN- $\lambda$ 1), Human;

### Description:

IL-28A, IL-28B, and IL-29, also named interferon- $\lambda$ 2 (IFN- $\lambda$ 2), IFN- $\lambda$ 3, and IFN- $\lambda$ 1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor  $\alpha$  (IL-10 R $\alpha$ ) and a novel IL-28 receptor  $\beta$  (IL-28 R $\beta$ ), also known as IFN- $\lambda$ 1. Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.

### Amino Acid Sequence:

```
00001  GPVPTSKPTT  TGKGCHIGRF  KSLSPQELAS  FKKARDALEE
00041  SLKLNWSCS  SPVFPGNWDL  RLLQVRERPV  ALEAELALTL
00081  KVLEAAAGPA  LEDVLDQPLH  TLHHILSQLQ  ACIQPQPTAG
00121  PRPRGRLHHW  LHRLQEAPKK  ESAGCLEASV  TFNLFRLLTR
00161  DLKYVADGNL  CLRTSTHPES  T
```

**Source:** *E. coli*

**Species:** Human

**Biological Activity:** Fully biologically active when compared to standard. The ED<sub>50</sub> as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml, corresponding to a specific activity of  $> 2.0 \times 10^5$  IU/mg.

**Molecular Weight:** Approximately 19.8 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids.

**Formulation:** Lyophilized from a 0.2  $\mu$ m filtered concentrated solution in PBS, pH 7.4.

**Appearance:** Sterile Filtered White lyophilized (freeze-dried) powder.

**Reconstitution:** We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at  $\leq -20$  °C. Further dilutions should be made in appropriate buffered solutions.

**Purity:**  $> 97$  % by SDS-PAGE and HPLC analyses.

**Endotoxin Level:** Less than 1 EU/ $\mu$ g of rHuIFN- $\lambda$ 1/IL-29 as determined by LAL method.

**Storage:** This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.